Study at a glance
What was studied?
Researchers examined how human immune cells obtain active vitamin D and affect one another. They tested how the surrounding conditions changed the response. Selected human trials measured an immune gene pattern, tuberculosis-related test results or respiratory infections.
What did the studies find?
Some stimulated T cells, a type of immune cell, could convert the form measured in blood into active hormone. Other cells supported conversion under different conditions. Proteins that bind vitamin D, cell stimulation and timing mattered. The selected human trials did not clearly improve their main outcomes.
What does this mean?
A laboratory marker does not guarantee lasting immune function or clinical benefit. One additional 2026 result favoured treatment. The authors said it would not remain statistically significant after adjusting for many comparisons. Such an adjustment addresses the risk of finding a positive result by chance when many comparisons are made.
What are the limits?
Many mechanisms were tested in small laboratory experiments. Human trials studied particular populations and outcomes. The evidence does not show the same effect on every immune response or identify a personal supplement dose or blood target.
Read the full article below ↓Vitamin D responses depend on communication between immune cells, local conversion to active hormone and the state of the cells receiving the signal. Human-cell experiments show several conditional routes linking innate and adaptive responses. Selected clinical trials test different outcomes and place limits on what those mechanisms can predict. Together, the evidence supports immune coordination with important boundaries, rather than one effect that applies to every cell, tissue or clinical setting. For the shorter account, read Vitamin D and Immune Coordination: Cell Context, Timing and Clinical Limits: Study Summary.
How vitamin D connects innate and adaptive responses
Vitamin D and Innate Immunity and Vitamin D and Adaptive Immunity describe two connected parts of the immune system. The experiments examined here focus on how cells from those systems influence one another. An antigen-presenting cell can affect a T cell’s access to active vitamin D, while an activated T cell can change the environment in which another immune cell processes vitamin D. The direction and size of a response depend on the particular interaction.
The molecular forms must be distinguished. Blood vitamin D status is commonly assessed using 25-hydroxyvitamin D, a precursor. Calcitriol is an active hormone that can act through the vitamin D receptor. Adding the precursor to a culture tests availability and conversion as well as the downstream response. Directly adding active hormone bypasses part of that sequence. Vitamin D Activation provides the conversion background and Vitamin D Receptors the receptor context.
These are not equivalent to randomizing people to oral vitamin D3. Culture medium, protein binding, activation signals and sampling time are experimentally controlled, while an intact person has interacting tissues and feedback. The studies are useful when the step each one actually tests remains explicit.
Antigen-presenting cells can support precursor responses
Jeffery and colleagues studied human T cells and dendritic cells, a type of antigen-presenting cell. Their experiments compared precursor and active-hormone exposure, different activation conditions, metabolite measurements and regulatory or inflammatory responses. Under the examined conditions, dendritic cells supported precursor-associated increases in regulatory markers and reductions in selected inflammatory T-cell outputs. These are specific cellular readouts, not evidence that every immune response decreased.
The study also examined conversion directly. Under an early sampling condition, active-metabolite production by isolated T cells was low or below the relevant detection limit, whereas the antigen-presenting-cell system was more responsive. That is evidence about those cells, conditions, assays and times. It does not establish that activated T cells permanently lack the capacity to convert the precursor.
Vitamin D-binding protein constrained availability and the resulting precursor-associated responses. Conversion-related interventions supported involvement of that step, but a pharmacological inhibitor does not provide the specificity of a perfectly selective genetic test. Small and varying donor numbers also limit precision. The experimental observations establish a conditional communication route, not a clinical tolerance treatment or a blood concentration target.
Activated T cells can also convert the precursor themselves
Kongsbak and colleagues supplied a direct qualification to an exclusive reliance on antigen-presenting cells. In isolated activated human T cells, expression of the activating machinery and active-metabolite production increased with time. Production was low at twenty-four hours and greater at forty-eight to seventy-two hours under their conditions.
Their experiments also compared protein and medium conditions. Vitamin D-binding protein constrained precursor-driven responses more than responses to directly supplied active hormone. Adding serum changed the precursor dose-response. This supports an availability limitation in that experimental system; it does not establish that every patient with a particular total blood result has the same intracellular exposure.
The later timecourse helps interpret the apparent difference from Jeffery’s early measurements. It does not prove that timing alone explains every discrepancy. T-cell selection, activation, serum conditions and assays also differed between papers. The studies therefore support conditional routes of activation, with particular experiments demonstrating autonomous T-cell conversion.
Macrophages and T cells modify each other’s environment
Lopez and colleagues extended the question to interactions between human macrophages and T cells. They compared experimentally generated macrophage states, precursor conversion, protein binding and coculture responses. The macrophage states differed substantially in conversion-related activity. T-cell coculture further increased metabolite generation in selected conditions.
Binding protein did not constrain every cell combination equally. Some combinations of activated macrophages and T cells maintained conversion and responses better than isolated T cells or the alternative macrophage state. In selected cocultures, precursor-associated suppression of interferon-gamma and increases in IL-5 and IL-13 persisted despite binding protein. These cytokine readouts were selective and did not establish a whole-person benefit. The resistance was relative: the results do not demonstrate unlimited availability or complete insensitivity to protein binding.
The familiar experimental labels M1 and M2 describe the culture conditions used in the paper. They should not be treated as fixed categories covering all human tissue macrophages. The cultures also combined cells from different donors, and some reported donor totals are difficult to reconcile into one aggregate participant count. The study provides controlled evidence of cell-state dependence, with no direct demonstration of whole-person clinical benefit.
Kongsbak and Lopez used distinct experiments but shared investigators and a Copenhagen research programme. Their findings should not be described as two independent laboratory replications of one result. Their scientific contribution lies in the different controlled comparisons and the limitations those comparisons place on an unconditional mechanism.
Complement-associated activation provides another local connection
Chauss and colleagues examined vitamin-D-associated responses in activated human T cells, including communication involving complement-related signalling and the CD46 molecule. They combined cellular perturbations with molecular measurements. The experiments supported involvement of local vitamin D signalling in selected changes from inflammatory programmes towards an IL-10-associated response.
Interleukin-10, abbreviated IL-10, is one of the signalling proteins called cytokines. The study also implicated IL-6 and STAT3, a cellular signalling protein, in the examined response. This matters because a cytokine often associated with inflammation can participate in a regulatory response under particular conditions. It would be misleading to describe vitamin D as uniformly suppressing every inflammatory signal.
Some genetic comparisons involved a single affected individual, and the molecular analyses generated many measurements. Those tests provide specific mechanistic clues without establishing population-wide clinical effects. The paper did not demonstrate a general conversion into a stable regulatory T-cell lineage, nor did it show that oral D3 produced a clinical benefit.
The narrower functional restraint question is examined in Vitamin D, CTLA-4 and Immune Restraint: Full Study. That article concerns removal of costimulatory molecules and responder-cell activation. The current review asks how local availability, cell communication and context shape the wider interpretation; it does not repeat that separate mechanism as a new standalone article.
Why availability and immune state change the response
The cell studies directly test several contextual variables: precursor versus active hormone, time after activation, protein binding, medium composition and the cells present. Their findings show that some apparently simple vitamin D effects depend on those conditions. They do not establish which variable explains every clinical trial difference.
A marker change does not establish a stable cell identity
Matos and colleagues studied precursor responses in sorted human T cells under conditions including only 2% human serum. The cells converted precursor and changed selected phenotypic markers. Transforming growth factor beta, or TGF-beta, is a signalling protein included in the experimental context. It influenced the response of FOXP3, a marker associated with regulatory T cells.
The investigators also examined methylation at selected regulatory regions, including the Treg-specific demethylated region. These measurements address chemical marks on particular DNA regions, not the entire epigenome. The examined loci did not acquire the vitamin-D-associated pattern expected for a natural regulatory T-cell identity under those conditions.
That result does not mean that no epigenetic change occurred anywhere. Nor does a marker increase prove durable tolerance. The authors’ suggestion that the phenotype might be transient is an inference; the study did not establish its long-term persistence in patients. The low serum fraction also prevents assuming unrestricted conversion under the protein-binding conditions of normal blood.
This paper supplies useful counterevidence to both a universal inability of T cells to activate the precursor and an overly strong interpretation of regulatory markers. Vitamin D and Immune Modulation provides the broader modulation context. The scientific distinction is between a measured cellular response, selected molecular features and a lasting clinical effect.
A rise in blood status did not clearly change the SLE immune signature
Aranow and colleagues randomized fifty-seven people with stable systemic lupus erythematosus, or SLE, and low screening vitamin D status to placebo or 2,000 or 4,000 international units (IU) of D3 daily for twelve weeks. Fifty-four contributed to the modified intention-to-treat analysis. The selected endpoint was an interferon-related gene-expression signature, rather than proof of improvement in every aspect of the disease. These amounts identify trial interventions and are not personal dose recommendations.
Blood 25-hydroxyvitamin D increased, but the pooled active groups did not show a clear advantage in the signature response compared with placebo; P=.53. The study was small and short, with quiet initial disease, background medicines, protocol deviations and missing expression data. It cannot exclude every modest or longer-term effect.
Its relevance is the separation of exposure and outcome. Changing a blood biomarker did not guarantee a detectable change in this selected immune measurement. The result also does not test every cellular route described earlier, so it cannot erase those experimental observations.
Baseline deficiency did not guarantee the tested preventive benefit
Ganmaa and colleagues randomized 8,851 Mongolian schoolchildren to 14,000 IU D3 weekly or placebo for three years. At baseline, 95.6% had blood 25-hydroxyvitamin D below 20 ng/mL. This makes the trial an important qualification to the claim that selecting a mostly deficient population necessarily produces a clinical benefit.
The primary outcome was conversion of a tuberculosis-related blood test in initially test-negative children. Conversion occurred in 147 of 4,074 children in the vitamin D group and 134 of 4,043 controls with the relevant final results. The adjusted risk ratio was 1.10, with a 95% confidence interval of 0.87 to 1.38 and P=.42. There was no clear difference in that primary comparison despite a substantial difference in achieved vitamin D status.
Test conversion is distinct from symptomatic disease, and the trial’s endpoint-specific disease and respiratory outcomes should retain their own uncertainty. Missing final tests and exploratory alternative-threshold analyses also require care. The result constrains a universal deficiency-correction argument without proving that vitamin D has no effect in every setting.
An offer of testing and supplements is a particular intervention
CORONAVIT randomized 6,200 UK adults to no offer or an offer of testing followed by D3 supplementation if the study’s eligibility criterion was met. The two offer groups used 800 or 3,200 IU daily when the measured blood form was below 75 nmol/L under the trial rule. The main intention-to-treat comparison included 5,979 participants. This was a pragmatic test-and-treat strategy, not a guarantee that every person assigned an offer took the same exposure.
Confirmed acute respiratory infection occurred in 4.6% of controls, 5.7% in the lower-regimen offer group and 5.0% in the higher-regimen offer group. The corresponding odds ratios against control were 1.26, with a 95% confidence interval of 0.96 to 1.66, and 1.09, with an interval of 0.82 to 1.46. The strategy did not show a clear preventive benefit in those comparisons.
The trial was open-label, and substantial supplement use in the control group reduced the exposure contrast. The planned baseline-status subgroup analysis could not validly be performed because the required control-group imputation was unsuccessful. The study’s eligibility threshold therefore cannot be converted into a proven immune-health target or a demonstrated subgroup effect.
The existing Study: Effect of test-and-treat vitamin D supplementation on SARS-CoV-2 vaccine efficacy and immunogenicity (CORONAVIT; Jolliffe et al., 2022) examines a vaccine ancillary study from the same parent trial. That is a different outcome within an overlapping population, not another independent trial confirming the current prevention result. Vaccine responses, infection events and a cell-culture cytokine response remain separate questions.
The 2026 dose-branch trial requires a primary-versus-secondary distinction
Meltzer and colleagues randomized 955 adults, with 923 receiving study vitamin D and included in the principal analysis. Before randomization, participants chose which dose-comparison branch to join: 4,000 versus 400 IU daily, or 10,000 versus 400 IU daily. Randomization then occurred within that branch, with follow-up up to nine months. Moderate versus high dose was therefore not itself a randomized comparison. Mean baseline 25-hydroxyvitamin D was 35.9 ng/mL, and 13.6% began below 20 ng/mL; this was not a predominantly deficient population.
The pooled primary comparison of moderate or high versus low dose gave an adjusted hazard ratio of 0.73 for reported COVID-19 incidence, with a 95% confidence interval of 0.51 to 1.06 and P=.10. The interval permits a potentially meaningful benefit as well as no clear effect; it does not prove zero benefit.
A prespecified secondary comparison in the moderate-dose branch gave an adjusted hazard ratio of 0.62, with an interval of 0.39 to 0.99 and P=.045. The high-dose branch estimate was 0.99, with an interval of 0.53 to 1.86. The authors stated that the moderate-branch result would not remain statistically significant after adjustment for multiple comparisons. Selecting the nominally positive result while omitting the pooled primary finding would misrepresent the evidence.
Recruitment was smaller than planned, registration occurred after initial enrolment, and infection ascertainment relied on participant reports and health records rather than universal serial testing. Branch choice, changing calendar context, wide intervals and post-hoc subgroup analyses limit claims about dose, sex, race or vaccination-related differences. The paper does not establish a dose optimum or prove that binding protein explains the clinical result.
Why timing, tissue and outcome choice matter
The preceding evidence contains several different reasons for disagreement. Some are experimentally demonstrated modifiers. Others concern study design, precision or hypotheses that have not been tested as mediators. Keeping those categories separate allows a useful explanation without claiming that all inconsistencies have been resolved.
| Evidence level | Examples in this review | Interpretation boundary |
|---|---|---|
| Availability and conversion | Precursor, active hormone, binding protein and timecourse experiments | Local culture exposure is not a personal blood target |
| Cell communication | Antigen-presenting-cell, macrophage and T-cell comparisons | Selected routes do not describe every immune cell |
| Molecular and phenotypic response | Cytokines, markers and selected DNA methylation | A marker change does not establish durable clinical tolerance |
| Human trial outcome | Immune signature, test conversion and respiratory infection | Population, comparator, primary analysis and uncertainty remain essential |
Timing is measured in some experiments and only proposed in others
Kongsbak’s timecourse directly showed low early conversion and greater later production in the selected activated T-cell system. This makes sampling time an experimentally supported variable. It also helps explain why an early sample cannot establish permanent lack of capacity. It does not prove that every difference from another paper was caused by time alone.
Clinical timing poses a different problem. A twelve-week gene-signature trial, a three-year infection-prevention trial and an offer-based respiratory-prevention trial do not test the same sequence. Differences in their outcomes cannot, by themselves, demonstrate that one began too late or used the correct schedule. Such an explanation would need a valid direct comparison or appropriately supported effect-modifier analysis.
These clinical examples address selected populations and outcomes, rather than establishing a pooled prevention effect. They do not establish a preferred supplement schedule or an immune-health blood threshold.
A blood measurement does not describe every tissue compartment
Chauss and colleagues also examined observational datasets from lung and blood in COVID-19. The cellular programme patterns differed between compartments. Those observations are relevant to tissue specificity, but they were not paired randomized tissue comparisons and did not establish that low serum 25-hydroxyvitamin D caused the lung pattern.
The inference from a circulating precursor to a local response involves several distinct quantities: availability, conversion, receptor-related responsiveness, cell composition and the selected downstream outcome. The studies directly test parts of that chain under controlled conditions. They do not measure all parts simultaneously in a supplemented patient.
Vitamin D Signalling Across Metabolism, Immunity and Endocrine Context: Evidence Review discusses related tissue-dependent vitamin D responses across organs. Here, the narrower evidence concerns coordination between immune cells and the limitations of predicting an immune endpoint from one circulating measurement. A plausible local mechanism should not be converted into proof of clinical mediation.
Molecular markers, cellular functions and clinical outcomes have different meanings
A change in an enzyme transcript is evidence about gene expression. A metabolite measurement in culture medium adds information about production and availability under those conditions. A cytokine or surface-marker change describes another selected response. A targeted methylation result addresses particular molecular regions. None automatically provides the result of a clinical trial.
Matos illustrates why a regulatory marker is insufficient to establish stable lineage. Aranow illustrates why a change in blood vitamin D status is insufficient to guarantee a particular immune-signature response. Ganmaa, CORONAVIT and Meltzer add tests of selected clinical or infection-related outcomes in different populations and intervention designs. These are complementary levels of evidence rather than interchangeable measures of ‘immunity’.
The same care applies to statistical negatives. A result that is not statistically clear is not proof of no possible effect. Its confidence interval, sample size, missing data and comparator determine what remains uncertain. Conversely, one nominally significant secondary result does not override a primary analysis, establish a subgroup treatment rule or resolve multiple-testing concerns.
What can explain differences, and what remains uncertain?
The evidence directly supports effects of time after activation, protein/medium conditions and selected cell-state contrasts in laboratory systems. It also documents tissue-associated programme differences and important clinical design limitations. It does not establish that these variables account for every difference between clinical trials or that adjusting them would produce a benefit.
Several research programmes are represented, with important relationships retained. Kongsbak and Lopez share a laboratory network; public datasets reused in molecular work are not new recruited populations; the CORONAVIT vaccine ancillary shares its parent trial; and multiple dose branches or post-hoc subsets from Meltzer remain one underlying study. Counting papers or analyses as independent votes would exaggerate the evidence.
Overall appraisal and clinical boundary
The principal strength of the cell evidence is the use of controlled contrasts and perturbations to distinguish availability, conversion, communication and selected downstream responses. Its limitations include small donor sets, strong experimental activation, artificial or diluted medium conditions, limited genetic samples and multiple molecular comparisons. Direct exposure to active hormone does not supply an oral supplement prescription.
The clinical studies make selected translation tests visible. They do not form a comprehensive review of all infection or autoimmune prevention and treatment. The results described here should not be generalized into universal benefit or universal ineffectiveness, and they do not identify a personal blood target. An individual clinical decision depends on evidence and circumstances beyond this mechanistic synthesis.
Conclusion
Vitamin D can participate in communication and conditional local responses across innate and adaptive cells. Availability, activation state, protein binding, time and tissue influence the interpretation. The clinical trials constrain translation from those mechanisms to outcomes in people. The combined evidence supports a specific, context-dependent account of immune coordination while leaving dose selection, treatment benefit and comprehensive clinical efficacy as separate questions.
Primary sources and publication details
Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. Jeffery LE and colleagues. Journal of Immunology. 2012;189:5155 to 5164. Author manuscript inspected. DOI: 10.4049/jimmunol.1200786. PMID: 23087405.
Vitamin D-binding protein controls T cell responses to vitamin D. Kongsbak M and colleagues. BMC Immunology. 2014;15:35. DOI: 10.1186/s12865-014-0035-2. PMID: 25230725.
Macrophages Control the Bioavailability of Vitamin D and Vitamin D-Regulated T Cell Responses. Lopez DV and colleagues. Frontiers in Immunology. 2021;12:722806. DOI: 10.3389/fimmu.2021.722806. PMID: 34621269.
Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells. Chauss D and colleagues. Nature Immunology. 2022;23:62 to 74. Author manuscript inspected. DOI: 10.1038/s41590-021-01080-3. PMID: 34764490.
Physiological levels of 25-hydroxyvitamin D3 induce a suppressive CD4+ T cell phenotype not reflected in the epigenetic landscape. Matos C and colleagues. Scandinavian Journal of Immunology. 2022;95:e13146. DOI: 10.1111/sji.13146. PMID: 35073416.
Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus. Aranow C and colleagues. Arthritis & Rheumatology. 2015;67:1848 to 1857. Author manuscript inspected. DOI: 10.1002/art.39108. PMID: 25777546.
Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease. Ganmaa D and colleagues. New England Journal of Medicine. 2020;383:359 to 368. Principal author-manuscript text inspected. DOI: 10.1056/NEJMoa1915176. PMID: 32706534.
Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT). Jolliffe DA and colleagues. BMJ. 2022;378:e071230. DOI: 10.1136/bmj-2022-071230. PMID: 36215226.
Effect of moderate or high versus low dose daily vitamin D on COVID-19 incidence: A double-blind, parallel-group randomized clinical trial. Meltzer DO and colleagues. Clinical Nutrition. 2026;64:106722. Accepted author manuscript inspected. DOI: 10.1016/j.clnu.2026.106722. PMID: 42480239.
Related reading
Vitamin D-binding protein controls T cell responses to vitamin D
In vitro studies have shown that the active form of vitamin D3, 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3), can regulate differentiation of CD4+ T cells by inhibiting Th1 and Th17 cell differentiation and promoting Th2 and Treg cell differentiation.
Original paper ↗Read more →Vitamin D and Immune Coordination: Cell Context, Timing and Clinical Limits: Study Summary
A plain-English summary of how vitamin D responses vary between immune cells, tissues and studies, and what these findings cannot establish.
Read more →Anti-Inflammatory Effects of Vitamin D on Human Immune Cells in the Context of Bacterial Infection
Vitamin D induces a diverse range of biological effects, including important functions in bone health, calcium homeostasis and, more recently, on immune function.
Original paper ↗Read more →Immune cells phenotype and bioenergetic measures in CD4+ T cells differ between high and low feed efficient dairy cows
The objectives of this study were to investigate immune cells phenotype and bioenergetic measures in CD4+ T cells in low feed efficient (LE) and high feed efficient (HE) dairy cows.
Original paper ↗Read more →Regulation of IL-17A Production Is Distinct from IL-17F in a Primary Human Cell Co-culture Model of T Cell-Mediated B Cell Activation
The aim of this study was to characterize the regulation of IL-17A and IL-17F in a model of T cell-dependent B cell activation.
Original paper ↗Read more →In Vivo Regulation of Signal Transduction Pathways by Vitamin D Stabilizes Homeostasis of Human Immune Cells and Counteracts Molecular Stress
Eight of the pathways show an approximately even contribution of up: and downregulated genes, suggesting that the actions of vitamin D stabilize homeostasis of the physiological processes driven by the respective signaling cascades.
Original paper ↗Read more →Vitamin D, B-Cell Function and the Limits of Immune Memory Evidence: Full Evidence Review
A review of B-cell experiments and vaccine trials, separating memory-cell markers and antibody changes from lasting protection against infection.
Read more →Vitamin D, B-Cell Function and the Limits of Immune Memory Evidence: Study Summary
Understand B-cell and vaccine findings, including null results, and why antibody changes do not establish durable protective immune memory.
Read more →The 1α,25-dihydroxyvitamin D3 modulates T cell activation and immune checkpoint pathways in human T cells
IC-related gene expression was evaluated by RT-qPCR.
Original paper ↗Read more →1,25-Dihydroxyvitamin D3 Restrains CD4+ T Cell Priming Ability of CD11c+ Dendritic Cells by Upregulating Expression of CD31
Dendritic cells (DC) are specialized sentinel cells that bridge the innate and adaptive immune response and play a crucial role in shaping the adaptive immune response.
Original paper ↗Read more →Anti-Inflammatory Effects of 1,25(OH)2D/Calcitriol in T Cell Immunity: Does Sex Make a Difference?
Hence, the aim of this study was to investigate whether calcitriol could act differently in modulating T cell immunity of age-matched male and female healthy donors.
Original paper ↗Read more →Effect of Vitamin D and Skeletal Muscle Mass on Prognosis of Patients with Diffuse Large B-Cell Lymphoma
This study investigated the prognostic impact of vitamin D deficiency and reduced skeletal muscle mass in diffuse large B-cell lymphoma (DLBCL) patients.
Original paper ↗Read more →Enhancement of Antiviral T-Cell Responses by Vitamin C Suggests New Strategies to Improve Manufacturing of Virus-Specific T Cells for Adoptive Immunotherapy
Since vitamins are described to influence the immune system and its cellular components, the aim of this study was to examine whether vitamins modulate virus-specific T-cell function and thereby enable an improvement of therapy.
Original paper ↗Read more →Human tolerogenic dendritic cell subtypes exert divergent effects on induction of cytotoxic CD4+ T cells
We compared human monocyte-derived tolDC generated with vitamin D3 alone or in combination with dexamethasone.
Original paper ↗Read more →Regulatory role of vitamin D in T-cell reactivity against myelin peptides in relapsing-remitting multiple sclerosis patients
The aim of this study was to determine the correlation between plasma 25(OH)D concentrations and clinical and immunological variables in a cohort of multiple sclerosis patients.
Original paper ↗Read more →Seasonal Variation in Vitamin D3 Levels Is Paralleled by Changes in the Peripheral Blood Human T Cell Compartment
Here, we investigated if and to what extent seasonality of vitamin D3 levels are associated with changes in T cell numbers and phenotypes.
Original paper ↗Read more →The Impact of Exosomes/Microvesicles Derived from Myeloid Dendritic Cells Cultured in the Presence of Calcitriol and Tacalcitol on Acute B-Cell Precursor Cell Lines with MLL Fusion Gene
Vitamin D analogs (VDAs) may directly inhibit the growth of normal and malignant (derived from acute lymphoblastic leukemia (ALL)) B cells, as both types of cells express vitamin D receptor (VDR).
Original paper ↗Read more →The vitamin D analogue calcipotriol promotes an anti-tumorigenic phenotype of human pancreatic CAFs but reduces T cell mediated immunity
The pancreatic tumour stroma is composed of phenotypically heterogenous cancer-associated fibroblasts (CAFs) with both pro: and anti-tumorigenic functions.
Original paper ↗Read more →Time-Resolved Gene Expression Analysis Monitors the Regulation of Inflammatory Mediators and Attenuation of Adaptive Immune Response by Vitamin D
Peripheral blood mononuclear cells (PBMCs) belong to the innate and adaptive immune system and are highly sensitive and responsive to changes in their systemic environment.
Original paper ↗Read more →Vitamin D in Cutaneous T-Cell Lymphoma
Cutaneous T-cell lymphoma (CTCL) is characterized by the proliferation of malignant T cells in inflamed skin lesions.
Original paper ↗Read more →Vitamin D and Adaptive Immunity
Learn how vitamin D relates to adaptive immunity, including its roles in T cells, B cells, antigen presentation, cytokine signalling, and immune memory.
Read more →Original sources
Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses
Published in Jeffery LE and colleagues. Journal of Immunology (2012).
Publication details
Availability of 25-hydroxyvitamin D(3) to APCs controls the balance between regulatory and inflammatory T cell responses. Jeffery LE and colleagues. Journal of Immunology. 2012;189:5155 to 5164. Author manuscript inspected. DOI: 10.4049/jimmunol.1200786. PMID: 23087405.
Vitamin D-binding protein controls T cell responses to vitamin D
Published in Kongsbak M and colleagues. BMC Immunology (2014).
Publication details
Vitamin D-binding protein controls T cell responses to vitamin D. Kongsbak M and colleagues. BMC Immunology. 2014;15:35. DOI: 10.1186/s12865-014-0035-2. PMID: 25230725.
Macrophages Control the Bioavailability of Vitamin D and Vitamin D-Regulated T Cell Responses
Published in Lopez DV and colleagues. Frontiers in Immunology (2021).
Publication details
Macrophages Control the Bioavailability of Vitamin D and Vitamin D-Regulated T Cell Responses. Lopez DV and colleagues. Frontiers in Immunology. 2021;12:722806. DOI: 10.3389/fimmu.2021.722806. PMID: 34621269.
Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells
Published in Chauss D and colleagues. Nature Immunology (2022).
Publication details
Autocrine vitamin D signaling switches off pro-inflammatory programs of TH1 cells. Chauss D and colleagues. Nature Immunology. 2022;23:62 to 74. Author manuscript inspected. DOI: 10.1038/s41590-021-01080-3. PMID: 34764490.
Physiological levels of 25-hydroxyvitamin D3 induce a suppressive CD4+ T cell phenotype not reflected in the epigenetic landscape
Published in Matos C and colleagues. Scandinavian Journal of Immunology (2022).
Publication details
Physiological levels of 25-hydroxyvitamin D3 induce a suppressive CD4+ T cell phenotype not reflected in the epigenetic landscape. Matos C and colleagues. Scandinavian Journal of Immunology. 2022;95:e13146. DOI: 10.1111/sji.13146. PMID: 35073416.
Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus
Published in Aranow C and colleagues. Arthritis & Rheumatology (2015).
Publication details
Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus. Aranow C and colleagues. Arthritis & Rheumatology. 2015;67:1848 to 1857. Author manuscript inspected. DOI: 10.1002/art.39108. PMID: 25777546.
Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease
Published in Ganmaa D and colleagues. New England Journal of Medicine (2020).
Publication details
Vitamin D Supplements for Prevention of Tuberculosis Infection and Disease. Ganmaa D and colleagues. New England Journal of Medicine. 2020;383:359 to 368. Principal author-manuscript text inspected. DOI: 10.1056/NEJMoa1915176. PMID: 32706534.
Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT)
Published in Jolliffe DA and colleagues. BMJ (2022).
Publication details
Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT). Jolliffe DA and colleagues. BMJ. 2022;378:e071230. DOI: 10.1136/bmj-2022-071230. PMID: 36215226.